Minirin is used as an antiduretic in the treatment of: diabetes insipidus of central genesis; with post-traumatic polyuria and polydipsia in the presence of transient insufficiency or the absence of antidiuretic hormone after hypophysectomy; after surgery in the area of the pituitary gland or traumatic brain injury.
The main active ingredient of the drug is desmopressin, in a dosage of 0.01% (0.1 mg of desmopressin acetate per ml, 1 ml of the drug contains 10 doses).
As auxiliary substances are: sodium chloride, citric acid monohydrate, sodium hydrogen phosphate dihydrate, benzalkonium chloride, purified water.
One bottle contains 50 doses of the drug.
The drug is produced in the form of a nasal spray, packaged in 5 ml vials.
Minirin belongs to a group of hormonal drugs that are used systemically and used as an antidiuretic.
Refers to the hormones of the posterior lobe of the pituitary gland (a gland that is located at the base of the brain and affects the development of the brain).
The main active ingredient of the drug is desmopressin, which is a structural analogue of the natural hormone arginine-vasopressin. Desmopressin is derived from changes in the construction of the vasopressin molecule.
This drug has the property of increasing the ability of the epithelium of the distal convoluted tubules to permeate water, which increases its ability to reabsorb.
Has the ability to reduce the volume of urine excreted by the body, and at the same time, to increase its osmolarity, while reducing the osmolarity of blood plasma.
Together, these properties cause a decrease in the amount of urination and a decrease in the amount of urine excreted.
Minirin is used as an antiduretic in the treatment of:
- diabetes insipidus of central genesis;
- with post-traumatic polyuria and polydipsia in the presence of transient insufficiency or the absence of antidiuretic hormone after hypophysectomy;
- after surgery in the area of the pituitary gland or traumatic brain injury.
It is also prescribed for an express test of the kidneys for their ability to concentrate, as well as for the differential diagnosis of diabetes insipidus.
It is prescribed for those patients who, due to their physical condition, cannot take desmopressin orally, in tablet form.
Not applicable if the patient has hypersensitivity (allergy) to one of the components that make up the drug.
Also does not apply if a person has:
- congenital polydipsia (insatiable thirst)
- psychogenic polydipsia;
- heart failure;
- other conditions that require diuretics;
- moderate renal failure;
- severe renal failure (with creatinine clearance lower than 50 ml per minute).
Application during pregnancy and lactation
It is undesirable to use Minirin for the treatment of pregnant women. For this category of patients, use is possible only if the potential benefit to the mother’s life is higher than the potential harm to the health of the fetus.
Breastfeeding is suspended while the drug is being used.
Method of administration and dosage
The dosage and duration of treatment with this drug is determined by the attending physician, who takes into account the individual nature of the course of the disease and the performance of the patient’s body as a whole.
When calculating the dosage, it should be borne in mind that 1 spray dose contains 0.1 ml of the drug, which corresponds to 10 μg of desmopressin.
In the treatment of diabetes insipidus, a drug is usually prescribed using the supplied dropper.
In this case, adults take 10-20 mcg, 1-2 times a day.
Children take 10 mcg 1-2 times a day.
If symptoms appear that indicate fluid retention in the body, or hyponatremia, treatment is stopped, after which the attending physician adjusts the previously prescribed dosage.
When used during testing for the ability of the kidneys to concentrate, the following dosages are applied:
- adults – 40 mcg;
- children under 1 year old – 10 mcg;
- children over 1 year old – 20 mcg.
After that, the urine collected during the first hour is not taken into account in testing. In the next 8 hours, 2 portions of urine are collected, which is checked for osmolarity.
At the same time, the patient’s fluid intake is monitored.
The test for newborns (under the age of 1 year) is carried out exclusively in a hospital setting, followed by strict control of the condition.
An overdose of the specified drug can cause symptoms such as:
- fluid retention;
Treatment is symptomatic.
If asymptomatic hyponatremia manifests itself, the drug is canceled, and fluid intake is limited.
In case of hyponatremia, infusion is performed using isotonic or hypertonic sodium chloride solution.
With severe fluid retention, which is characterized by convulsions, loss of consciousness, it is permissible to use furosemide.
To prevent overdose in children, the dosage is measured by adults.
Therapy with this drug can cause side reactions in the form of:
- fluid retention;
- increased pressure, hot flashes;
- headache, seizures;
- rhinitis, nosebleeds;
- dry throat;
- nausea, vomiting, abdominal pain;
- pain in the vulva;
- increased sweating;
- increase in body weight;
- emotional disorders (in childhood).
If you experience any unusual side effects as a result of taking this drug, you should consult your doctor about possible changes in the treatment regimen.
Storage conditions and periods
The shelf life of the drug Minirin is no more than 2 years from the production date indicated on the package.
Store in a dry place out of the reach of children, at a temperature not exceeding 25 ° C. After opening, the drug is stored for 2 months at the same temperature.
Do not freeze!